-
Ganetespib (STA-9090) Research Workflows
2026-09-29
Build more informative cancer research assays with Ganetespib (STA-9090), from controlled Hsp90 inhibition and dose-response profiling to orthogonal measurements of client-protein loss and cell death. A recent norovirus study adds a useful assay-design lesson: extracellular signals should be interpreted alongside intracellular and membrane-integrity controls rather than treated as interchangeable readouts.
-
Imatinib hydrochloride: Applied Research Workflows
2026-09-28
Build more interpretable CML and GIST experiments with a target-informed Imatinib hydrochloride workflow, from dose selection to phospho-signaling and viability readouts. A recent p38α study adds a useful assay-design lesson about kinase conformation and dephosphorylation—but does not establish that imatinib has this dual action.
-
Enhanced ECL Detection Kit: Workflow and Limits
2026-09-27
The ECL Chemiluminescent Substrate Detection Kit (Enhanced) supports sensitive detection of HRP-labeled antibodies and low-abundance proteins in western blots, with luminescence lasting up to 5 hours. Use it for HRP-based chemiluminescent protein immunodetection; it is not a substitute for fluorescence or non-HRP detection reagents.
-
In Vitro Induction of Mammalian Embryonic Dormancy
2026-09-26
This Nature Protocols paper describes in vitro methods for inducing and reversing a diapause-like dormant state in mouse blastocysts, human blastoids, and mouse and human pluripotent stem cells through pharmacological mTOR inhibition. The workflow offers a more accessible, scalable way to study embryonic dormancy than surgery-based in vivo approaches, while emphasizing model-specific conditions and careful assessment of reversibility and developmental competence.
-
AO/PI Staining Solution for Cell Viability Workflows
2026-09-26
AO/PI Staining Solution uses two fluorescent DNA dyes to distinguish membrane-intact from membrane-compromised cells, helping reduce counting errors from debris and red blood cell interference. See how to apply this fluorescence-based readout to hyperglycemia-stressed podocyte workflows—and where it complements, rather than replaces, apoptosis and signaling assays.
-
Trilaurin (Glycerol Tridodecanoate) Workflow Guide
2026-09-25
Trilaurin (Glycerol Tridodecanoate, BA7536) provides a water-insoluble lipid material for nonaqueous stock preparation, biocatalytic work, and lipid-particle formulation. It is not suitable for aqueous-only stocks, and prepared solutions are intended for short-term use rather than long-term storage.
-
Infigratinib Reverses ABCB1-Mediated Drug Resistance
2026-09-25
Boichuk and colleagues report that infigratinib (BGJ 398) can restore the effects of paclitaxel and doxorubicin in ABCB1-overexpressing tumor cells by impairing drug efflux, without reducing ABCB1 expression. The study distinguishes this effect from FGFR pathway suppression alone: PD 173074 did not reproduce the drug-retention or chemosensitizing results in the tested resistant cells.
-
Phosphatase Inhibitor Cocktail 3 for OGD Studies
2026-09-24
Preserve phosphorylation during neuronal oxygen-glucose deprivation (OGD) sample preparation with a 100X cocktail formulated to inhibit alkaline phosphatases and serine/threonine phosphatases including PP1 and PP2A. This workflow connects ferroptosis-focused OGD experiments with carefully controlled phosphoprotein analysis—without mistaking phosphatase inhibition for a direct ferroptosis readout.
-
SLC2A5 Fructose Metabolism in Primary CNS Lymphoma
2026-09-24
Single-cell profiling links the glucose-poor, hypoxic primary CNS lymphoma microenvironment to increased SLC2A5-mediated fructose metabolism in lymphoma cells and tumor-supportive macrophages. Functional experiments identify this pathway as a potential metabolic vulnerability, while leaving important questions about patient selection and clinical translation unresolved.
-
ETS1–SENP2 Control of Mitophagy in BPD
2026-09-23
The reference study identifies ETS1 as a transcriptional regulator of mitochondrial quality control in hyperoxia-induced bronchopulmonary dysplasia. Its central mechanism links ETS1-driven SENP2 expression to FUNDC1 deSUMOylation, HSPA8-dependent FUNDC1 degradation, and suppression of excessive mitophagy.
-
U-73122: From PLC Signaling to Invasion
2026-09-23
U-73122 is a phospholipase C inhibitor for probing calcium signaling, chemotaxis, inflammation, and cancer-cell invasion. This article develops an evidence-based framework for interpreting PLC inhibition as a causal assay variable rather than treating it as a simple endpoint reagent.
-
Okadaic acid (A4540): PP1/PP2A Workflow
2026-09-22
Okadaic acid (A4540) provides a defined way to reduce PP2A-dominant or combined PP1/PP2A serine/threonine phosphatase activity in biochemical and cell-based assays. It is appropriate for phosphorylation, apoptosis, and signal-transduction workflows with matched controls, but biochemical IC50 values should not be treated as universal cellular treatment doses or as evidence of broad phosphatase inhibition.
-
Necrostatin 2: Practical Necroptosis Workflows
2026-09-21
Necrostatin 2 (Nec-2) provides a practical chemical probe for dissecting RIPK2-associated programmed necrotic cell death, with particular value in ischemic stroke research and pathway validation. This guide shows how to prepare, dose, benchmark, and troubleshoot Nec-2 while distinguishing necroptosis from ferroptotic membrane failure.
-
EZ Cap™ Mouse CD80 mRNA: Assay Design
2026-09-21
EZ Cap™ Mouse CD80 mRNA (m1Ψ, HA tag) enables controlled studies of CD80-dependent co-stimulation. This guide presents a measurement-centered framework that links HA-tag verification, T-cell functional assays, and longitudinal interpretation without overextending published mRNA-immunotherapy findings.
-
Erastin: Designing Interpretable Ferroptosis Assays
2026-09-20
Erastin is a ferroptosis inducer used to investigate how cystine metabolism, glutathione loss, and oncogenic signaling create tumor-cell vulnerability. This guide focuses on assay interpretation, evidence-based controls, and translating ferroptosis research into more defensible cancer biology experiments.